A Male Case with Type 2 Diabetes (T2D), Hypertension and Fatty Liver Treated By Vildagliptin/Metformin (Equmet)

Iwatsuki N, Bando H, Okada M, Ogawa T and Sakamoto K

Published on: 2025-10-22

Abstract

The case is 61-year-old male with type 2 diabetes (T2D), hypertension, fatty liver, urolithiasis and cholelithiasis. He was treated by oral hypoglycemic agents (OHAs) of vildagliptin/metformin (EquMet). HbA1c recently showed about 6.6-7.4%. Body weight was 57kg in 20s, which gradually increased during 30s-50s, and the max was 70kg in 50s. Current weight is 68.1kg with 25.3 kg/m² in BMI. Pulse wave velocity (PWV) showed 1.11/1.16 as ankle-brachial index (ABI), and 9.8/9.6 as Cardio-Ankle Vascular Index (CAVI) with arteriosclerosis. EquMet shows notable feature for twice daily administration, where mean amplitude of blood glucose excursions (MAGE) is lowered during night time.